Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
FRTX was delisted on the 18th of December, 2023.
22 hedge funds and large institutions have $899K invested in Fresh Tracks Therapeutics, Inc. Common Stock in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.
0% more funds holding
Funds holding: 22 → 22 (0)
0% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 8
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
63% less capital invested
Capital invested by funds: $2.44M → $899K (-$1.54M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$101K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$30.5K |
| 3 |
Jane Street
New York
|
+$28K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$26.2K |
| 5 |
State Street
Boston,
Massachusetts
|
+$19.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$380K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$167K |
| 3 |
TI
Telemetry Investments
New York
|
-$165K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$37K |
| 5 |
WIC
Water Island Capital
New York
|
-$27K |
FRTX Hedge Fund Activity: Q2 2022 in Review
22 of the 5,937 institutional investors tracked by Wall St. Rank reported a position in Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) for Q2 2022, worth a combined $899K — down 63% from $2.44M a quarter earlier.
Fund positioning in FRTX was balanced in Q2 2022: 8 funds opened new positions, 8 closed out, 4 added to existing stakes and 4 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $101K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $380K sold.
- 22 institutional investors held Fresh Tracks Therapeutics, Inc. Common Stock (FRTX) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $899K of Fresh Tracks Therapeutics, Inc. Common Stock stock for Q2 2022, down 63% quarter-over-quarter.
- 8 funds opened new Fresh Tracks Therapeutics, Inc. Common Stock positions in Q2 2022 and 8 closed out, a net change of 0 holders.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock buyer in Q2 2022 was Millennium Management, an estimated $101K added.
- The largest Fresh Tracks Therapeutics, Inc. Common Stock seller in Q2 2022 was Renaissance Technologies, an estimated $380K sold.
Based on aggregated 13F filings for Q2 2022.